Brooks Laboratorie has informed that it enclosed update under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements, 2015) regarding approval for Meropenem Injection 500mg per via land 1 gram per vial (the product) from the United States Food & Drug Administration (USFDA).
The above information is a part of company’s filings submitted to BSE.